Komori
Immuno-Biological Laboratories (4570) · RiskRestated

Recoverability of deferred tax assets and estimates of future taxable income

First written in FY2024. 2 of 3 entries say "Restated". Latest entry: FY2026.

3entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2024 – FY20262024: 120242025: 120252026: 12026
Same theme, other companies

The whole theme swung hardest in 2020: 20 of 62 companies on the "Worse" side.

72 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 199 companies compared. The sentences above are computed from all 199.Comparing 200 of the theme's 320 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「Because the recoverability of deferred tax assets depends on estimates of future taxable income, any change in the assumptions underlying those estimates could have a material impact on the amounts of deferred tax assets and deferred income taxes in the consolidated financial statements for the following consolidated fiscal year.」

    Net deferred tax assets increased to ¥145.412 million, but the Company continues to disclose the recoverability risk arising from dependence on business-plan assumptions, including future sales, selling, general and administrative expenses, and operating profit margins.
  2. FY2025RestatedAnnual report

    「Because the recoverability of deferred tax assets depends on estimates of future taxable income, any change in the assumptions underlying those estimates could have a material impact on the amounts of deferred tax assets and deferred income taxes in the consolidated financial statements for the following consolidated fiscal year.」

    Net deferred tax assets increased from ¥67.908 million to ¥112.338 million, but the Company continues to disclose the risk that their recoverability depends on business-plan assumptions, including future sales, selling, general and administrative expenses, and operating profit margins.
  3. FY2024First statedAnnual report

    「Because the recoverability of deferred tax assets depends on estimates of future taxable income, any change in the assumptions underlying those estimates could have a material impact on the amounts of deferred tax assets and deferred income taxes in the consolidated financial statements for the following consolidated fiscal year.」

    While recognising deferred tax assets of ¥67.908 million in the current fiscal year, the Company newly specified the risk that their recoverability depends on business-plan assumptions, including future sales, selling, general and administrative expenses, and operating profit margins.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Immuno-Biological Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Recoverability of deferred tax assets and estimates of future taxable income | Immuno-Biological Laboratories Co.,Ltd. (4570) | Komori